Abstract:Background: Angiogenesis plays a key role in growth and metastasis of many tumors and is generally mediated by a variety of growth factors, including vascular endothelial growth factor (VEGF) and fibroblast growth factor (FGF). Sulfatinib is a highly selective small molecule dual inhibitor of VEGF receptor (VEGFR) and FGF receptor (FGFR), developed by Hutchison MediPharma. It demonstrated potent in vivo inhibitory effects on a variety of human tumor xenografts. The current study was designed to evaluate safety and tolerability, pharmacokinetics, and preliminary anti-tumor activity of sulfatinib. Methods: Eligible patients with histopathologically confirmed solid tumors that had previously failed standard therapies or for whom no standard therapies were available were to be enrolled in cohorts of escalating sulfatinib doses given orally once or twice daily of 28-day cycles until disease progression or unacceptable toxicity. Modified Fibonacci method was used for dose escalation, followed by an expanded cohort at the maximum tolerated dose (MTD). Results: As of Aug 31, 2011, 28 patients have been enrolled in 8 sulfatinib dose cohorts of 50, 75, 110, 150, 200, 265 and 300mg once daily (QD) and 125mg twice daily (BID), respectively. Patients had a median age of 50 (36–70) yrs, with 46% male, ECOG performance status 0–2, and predominantly heavily pretreated. Patient tumor types included colorectal (9), GIST (5), liver (4), neuroendocrine (4), gastric (1), esophageal (1), duodenal (1), cervical (1), retroperitoneal liposarcoma (1), and solid-pseudopapillary tumor of the pancreas (1). Common adverse events (AEs) included fatigue, vomiting, nausea, diarrhea, hypertension, electrolyte disorder and elevated AST/ALT, mostly grade 1/2. Serious AEs and drug related grade 3 AEs were identified in 2 and 5 patients, respectively. Two dose limiting toxicities including a grade 3 coagulation disorders and a grade 3 upper gastrointestinal bleeding were observed in the 50 mg and 265mg cohort, respectively. No unexpected AE has been identified. MTD has not been reached and the dose escalation is ongoing at 300 mg QD and 125mg BID. Among 24 evaluable patients, 7 (29%) had stable disease, with the duration up to 5 months. Five of 9 (56%) patients at doses of ≥ 200mg had stable disease in comparison with 2/15 (13%) patients at doses of Conclusions: Sulfatinib was well tolerated at doses up to 265 mg QD and demonstrated preliminary evidence of anti-tumor activity. PD marker analysis indicates dual inhibition of VEGFR and FGFR. Preliminary PK data suggests good dose proportionality in exposure without marked drug accumulation over the evaluated doses. Dose escalation is ongoing at 300 mg QD and 125mg BID. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; 2011 Nov 12-16; San Francisco, CA. Philadelphia (PA): AACR; Mol Cancer Ther 2011;10(11 Suppl):Abstract nr C198.

A Phase II Multicenter Trial of the Multitargeted Kinase Inhibitor Sulfatinib in Advanced Medullary Thyroid Cancer (MTC) and Radioiodine (Rai)-Refractory Differentiated Thyroid Cancer (DTC).

First-in-human Phase I Study of a Selective VEGFR/FGFR Dual Inhibitor Sulfatinib in Patients with Advanced Solid Tumors.

Surufatinib in Chinese Patients with Locally Advanced or Metastatic Differentiated Thyroid Cancer and Medullary Thyroid Cancer: A Multicenter, Open-Label, Phase II Trial

Abstract C198: Phase I study on safety and pharmacokinetics of sulfatinib, a selective VEGFR/FGFR dual inhibitor, in Chinese patients with advanced solid tumors.

Phase Ii Study of Anlotinib for Treatment of Advanced Medullary Thyroid Carcinoma.

Sulfatinib, a Novel Kinase Inhibitor, in Patients with Advanced Solid Tumors: Results from a Phase I Study

A Phase I/II Trial of Sapanisertib in Advanced Anaplastic and Radioiodine Refractory Differentiated Thyroid Carcinoma

Anlotinib for the Treatment of Patients with Locally Advanced or Metastatic Medullary Thyroid Cancer.

Anlotinib Treatment In Locally Advanced Or Metastatic Medullary Thyroid Carcinoma: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase Iib Trial.

Anlotinib in Locally Advanced or Metastatic Medullary Thyroid Carcinoma: A Randomized, Double-Blind Phase IIB Trial

Phase Ib/IIa Study Assessing the Safety and Efficacy of AL8326 Monotherapy in Patients with ≥3rd Line Small Cell Lung Cancer (SCLC) Treatment.

Phase Ia/Ib Study of the Selective MET Inhibitor, Savolitinib, in Patients with Advanced Solid Tumors: \nSafety, Efficacy, and Biomarkers

First-in-human (FIH) Phase I Study of a Selective VEGFR/FGFR Dual Inhibitor Sulfatinib with Milled Formulation in Patients with Advanced Solid Tumors.

A Phase II Trial of Sitravatinib Plus Nivolumab after Progression on Prior Immune Checkpoint Inhibitor (ICI) in Patients with Metastatic Clear Cell Renal Cell Carcinoma (Ccrcc).

A Multicenter, Single-Arm Phase 2 Study of Surufatinib Plus Toripalimab for Patients with Locally Advanced or Metastatic Radioactive Iodine-Refractory Differentiated Thyroid Cancer

Efficacy and Safety of Surufatinib for Recurrent or Metastatic Malignant Salivary Gland Tumors: An Open-Label, Single-Arm, Phase II Study

Anlotinib in Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Carcinoma: A Randomized, Double-Blind, Multicenter Phase II Trial

Anlotinib in Locally Advanced or Metastatic Radioiodinerefractory Differentiated Thyroid Carcinoma: A Randomized, Double-Blind, Multicenter Phase II Trial

A Phase 2a Study Evaluating the Efficacy and Safety of Sutetinib in Patients with Advanced Non–small-Cell Lung Cancer (NSCLC) Harboring Uncommon EGFR Mutations.

Efficacy and Safety of Second-Line Treatment with Surufatinib for Anlotinib-Resistant Radioiodine-Refractory Differentiated Thyroid Cancer: an Exploratory Multicenter Study.

A Phase II Study of Surufatinib in Patients with Osteosarcoma and Soft Tissue Sarcoma Who Have Experienced Treatment Failure with Standard Chemotherapy